Resistant mutants induced by adefovir dipivoxil in hepatitis B virus isolates

Table 3 Clinical features of single mutant and multi-mutant groups n (%)

Clinical features	Single mutant(n = 53)	Multi-mutants(n = 26)	Statistical value	P-value
Gender (M/F)	45/8	21/5	χ2 = 0.217	0.749
Age (yr, mean ± SD)	42.6 ± 10.5	44.5 ± 8.9	t = 0.806	0.423
End-stage liver disease1	21 (39.62)	11 (42.31)	χ2 = 0.721	0.396
NAFLD	19 (35.85)	11 (42.31)	χ2 = 0.137	0.712
E-antigen (+/–)	24/29	12/14	χ2 = 0.005	1.000
Genotype (B/C)	10/43	6/20	χ2 = 0.022	0.883
HBV-DNA (log10 copy/mL)	5.06 ± 1.24	5.35 ± 1.21	t = 0.989	0.326
Duration of treatment (mo, mean ± SD)	38.6 ± 8.2	43.9 ± 10.8a	t = 2.426	0.018

¹End-stage liver disease: included hepatitis cirrhosis, liver failure, and primary hepatocellular carcinoma.

^aP < 0.05 duration of treatment in the single mutant group vs the multi-mutants group. NAFLD: Non-alcoholic fatty liver disease; HBV: Hepatitis B virus.